Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEONNASDAQ:CDIONYSE:CVMNASDAQ:SNYR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEONAEON Biopharma$0.74-3.4%$0.57$0.38▼$269.28$8.41M0.571.03 million shs229,883 shsCDIOCardio Diagnostics$3.71-4.6%$7.40$3.40▼$53.10$6.46M3.1294,895 shs25,237 shsCVMCEL-SCI$2.55+11.4%$5.27$1.98▼$66.60$7.73M0.2775,081 shs381,502 shsSNYRSynergy CHC$2.65+19.9%$2.06$0.36▼$10.00$24.35MN/A83,082 shs215,303 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEONAEON Biopharma0.00%-18.36%+39.33%+2.79%-99.05%CDIOCardio Diagnostics0.00%-8.62%-6.08%-71.38%-79.39%CVMCEL-SCI0.00%+13.33%+1.59%-68.08%-93.41%SNYRSynergy CHC0.00%+27.40%+35.20%-8.18%+26,400.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEONAEON Biopharma3.3282 of 5 stars3.52.00.00.03.41.71.9CDIOCardio Diagnostics2.4943 of 5 stars3.52.00.00.02.81.70.6CVMCEL-SCI0.0566 of 5 stars0.02.00.00.00.00.00.6SNYRSynergy CHC3.7253 of 5 stars3.80.00.00.02.53.31.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEONAEON Biopharma 3.00Buy$360.0048,287.10% UpsideCDIOCardio Diagnostics 3.00Buy$60.001,517.25% UpsideCVMCEL-SCI 0.00N/AN/AN/ASNYRSynergy CHC 3.50Strong Buy$10.00277.36% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEONAEON BiopharmaN/AN/AN/AN/A($4.12) per shareN/ACDIOCardio Diagnostics$40K161.39N/AN/A$7.10 per share0.52CVMCEL-SCIN/AN/AN/AN/A$0.15 per shareN/ASNYRSynergy CHC$34.83M0.70$0.27 per share9.96($1.91) per share-1.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEONAEON Biopharma-$36.63M$298.124.13N/AN/AN/AN/A-994.63%8/11/2025 (Estimated)CDIOCardio Diagnostics-$8.38MN/A0.00∞N/A-28,539.39%-84.55%-74.63%8/12/2025 (Estimated)CVMCEL-SCI-$26.92M-$12.61N/AN/AN/AN/A-238.05%-104.65%N/ASNYRSynergy CHC$2.12MN/A0.004.49N/AN/A-8.48%12.75%N/ALatest AEON, SNYR, CDIO, and CVM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025CDIOCardio Diagnostics-$0.06-$0.97-$0.91-$0.97$0.05 million$0.00 million5/15/2025Q1 2025SNYRSynergy CHC$0.07$0.10+$0.03$0.10$9.03 million$8.17 million3/31/2025Q4 2024SNYRSynergy CHC$0.10$0.01-$0.09$0.01$10.55 million$10.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEONAEON BiopharmaN/AN/AN/AN/AN/ACDIOCardio DiagnosticsN/AN/AN/AN/AN/ACVMCEL-SCIN/AN/AN/AN/AN/ASNYRSynergy CHCN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEONAEON BiopharmaN/A0.220.22CDIOCardio DiagnosticsN/A19.4719.47CVMCEL-SCI0.661.071.09SNYRSynergy CHCN/A1.911.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEONAEON Biopharma22.78%CDIOCardio Diagnostics8.06%CVMCEL-SCI12.08%SNYRSynergy CHCN/AInsider OwnershipCompanyInsider OwnershipAEONAEON Biopharma0.86%CDIOCardio Diagnostics22.30%CVMCEL-SCI9.93%SNYRSynergy CHC56.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEONAEON Biopharma511.31 million74.37 millionNot OptionableCDIOCardio Diagnostics11.74 million1.35 millionNot OptionableCVMCEL-SCI433.03 million64.67 millionOptionableSNYRSynergy CHC409.19 million3.99 millionN/AAEON, SNYR, CDIO, and CVM HeadlinesRecent News About These CompaniesSynergy CHC (NASDAQ:SNYR) Upgraded to "Buy" at Wall Street ZenJune 22 at 1:45 AM | americanbankingnews.comSynergy CHC (NASDAQ: SNYR) Expands FOCUSfactor® to UAE & Turkey — Ignites Global Growth and New Revenue StreamsJune 18, 2025 | finance.yahoo.comSynergy CHC Corp. Expands International Licensing Deal with Gravity Pharma to Include Turkey, Securing $2 Million in RevenueJune 18, 2025 | quiverquant.comHere is What You Need to Know Before Investing in Synergy CHC Corp. (SNYR)June 18, 2025 | finance.yahoo.comHere is What You Need to Know Before Investing in Synergy CHC Corp. (SNYR)June 16, 2025 | insidermonkey.comSynergy CHC Corp. (Uplisting) (NASDAQ:SNYR) CEO Jack Ross Buys 9,400 SharesJune 12, 2025 | insidertrades.comNew to The Street TV Spotlights Synergy CHC (NASDAQ:SNYR) as Former Coca-Cola Executive Joins to Drive FOCUSfactor(R) Energy Drink’s Global ExpansionJune 11, 2025 | freep.comNew to The Street TV Spotlights Synergy CHC (NASDAQ:SNYR) as Former Coca-Cola Executive Joins to Drive FOCUSfactor(R) Energy Drink's Global ExpansionJune 10, 2025 | guardonline.comSynergy CHC Corp. Appoints Damian Marano as Vice President of Beverage to Accelerate Functional Beverage ExpansionJune 10, 2025 | quiverquant.comSynergy CHC (NASDAQ: SNYR) Taps Former Coca-Cola Executive to Help Drive FOCUSfactor Energy Drink Global ExpansionJune 10, 2025 | globenewswire.comSynergy CHC secures $20 million loan for growth and debt repaymentJune 6, 2025 | investing.comSynergy CHC Secures $20 Million Loan AgreementJune 4, 2025 | msn.comSynergy CHC Announces New $20 Million Long-Term Credit FacilityJune 4, 2025 | globenewswire.comSNYR Synergy CHC Corp.May 30, 2025 | seekingalpha.comSynergy CHC Announces Appointment of Erik Shields as Vice President of BeverageMay 29, 2025 | finance.yahoo.comSynergy CHC Corp. (Uplisting) (NASDAQ:SNYR) CEO Jack Ross Buys 5,000 SharesMay 22, 2025 | insidertrades.comAnalysts Offer Insights on Consumer Goods Companies: Wilmar International (OtherWLMIF) and Synergy CHC (SNYR)May 21, 2025 | theglobeandmail.comSynergy CHC Corp (SNYR) Q1 2025 Earnings Call Highlights: Navigating Revenue Challenges with ...May 16, 2025 | uk.finance.yahoo.comSynergy CHC Corp. Reports Strong Q1 2025 EarningsMay 16, 2025 | tipranks.comSynergy CHC Corp Reports Growth in Earnings Per Share for its First Quarter 2025 Financial Results and its Ninth Consecutive Quarter of ProfitabilityMay 15, 2025 | manilatimes.netNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAEON, SNYR, CDIO, and CVM Company DescriptionsAEON Biopharma NASDAQ:AEON$0.74 -0.03 (-3.38%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.84 +0.09 (+12.63%) As of 06/20/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.Cardio Diagnostics NASDAQ:CDIO$3.71 -0.18 (-4.63%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$3.76 +0.05 (+1.24%) As of 06/20/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.CEL-SCI NYSE:CVM$2.55 +0.26 (+11.35%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$2.46 -0.09 (-3.33%) As of 06/20/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.Synergy CHC NASDAQ:SNYR$2.65 +0.44 (+19.91%) As of 06/20/2025 04:00 PM EasternSynergy CHC Corp. engages in the marketing and distribution of branded health and wellness products. The company was founded on December 29, 2010 and is headquartered in Westbrook, ME. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
